<Suppliers Price>

LX7101

Names

[ CAS No. ]:
1192189-69-7

[ Name ]:
LX7101

[Synonym ]:
LX7101
3-(4-(aminomethyl)-1-(5-methyl-7H-pyrrolo[2,3-d]pyrimidin-4-yl)piperidine-4-carboxamido)phenyl dimethylcarbamate
3-(4-(aminomethyl)-1-(5-methyl-7H-pyrrolo[2,3-d]pyrimidin-4-yl)piperidine-4-carboxamido)phenyldimethylcarbamate

Biological Activity

[Description]:

LX7101 is a potent inhibitor of LIMK and ROCK2 with IC50 values of 24, 1.6 and 10 nM for LIMK1, LIMK2 and ROCK2, respectively; also inhibits PKA with an IC50 less than 1 nM.

[Related Catalog]:

Signaling Pathways >> Cell Cycle/DNA Damage >> ROCK
Signaling Pathways >> Stem Cell/Wnt >> ROCK
Signaling Pathways >> TGF-beta/Smad >> ROCK
Research Areas >> Others

[Target]

ROCK2:10 nM (IC50)

LIMK2:1.6 nM (IC50)

LIMK1:24 nM (IC50)

PKA:1 nM (IC50)


[In Vitro]

LX7101 is a dual LIM-kinase and ROCK inhibitor for the treatment of ocular hypertension and associated glaucoma. LX-7101 also displays potent inhibition of Akt1 with an IC50 of less than 1 nM[1]. The overall selectivity of LX7101 for LIMK2 increases at the higher physiological ATP concentrations. Under physiological conditions, the activity of LX7101 is primarily due to inhibition of LIMK2[2].

[In Vivo]

LX-7101 is advanced to Phase-I clinical trials as an intraocular pressure (IOP)-lowering agent for treatment of glaucoma. LX-7101 displays a significant IOP reduction at time points ranging from 1 h to 6 h post administration in rabbits[1]. Topical doses of LX-7101 are evaluated for tolerability on the eyes of mice, rats, and rabbits. It is well tolerated at doses up to 0.5% in non-GLP single dose studies. In the mouse IOP assay, LX-7101 (5%) achieved additional reduction of IOP (5.0 mmHg total reduction) compared to the 0.1% formulation and demonstrated a long duration of action, with IOP not returning to baseline until more than 8 h postdose[2].

[References]

[1]. Boland S, et al. Design, synthesis and biological characterization of selective LIMK inhibitors. Bioorganic & Medicinal Chemistry Letters (2015), 25(18), 4005-4010.

[2]. Harrison BA, et al. Discovery and Development of LX7101, a Dual LIM-Kinase and ROCK Inhibitor for the Treatment of Glaucoma. ACS Medicinal Chemistry Letters (2015), 6(1), 84-88.


[Related Small Molecules]

Y-27632 2HCl | Fasudil Hydrochloride | KD025(SLx-2119) | Narciclasine | Y-39983 HCl | Thiazovivin | GSK429286A | GSK180736A | GSK 269962 | SR-3677 | TC-S 7001 | K-115 | RKI-1447 | Chroman 1 | H-1152 (dihydrochloride)

Chemical & Physical Properties

[ Molecular Formula ]:
C23H29N7O3

[ Molecular Weight ]:
451.52100

[ Exact Mass ]:
451.23300

[ PSA ]:
129.47000

[ LogP ]:
3.34900

[ Storage condition ]:
2-8℃


Related Compounds